Welcome to PulmoRay

Learn more about what we do

Add a description here.

Read more

About Us

PulmoRay is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on developing novel treatments of pulmonary arterial hypertension (PAH),

Pipeline

Learn more about what we do

Science

Learn more about what we do

Investors

Learn more about what we do

Contact Us

Write something in this area.

Message Sent!

Your message has been sent successfully, I hope to respond within 24 hours. You can also contact us through social media, links can be found below!

Introduce your team

Do you work with an awesome team? Of course you want to introduce them to your visitors.

Add a description here.

Team member

Job title or function

Team member

Job title or function

Team member

Job title or function

200 mg Sainsbury

Pulmonary hypertension

Pulmonary hypertension, the occurrence of high blood pressure in the pulmonary arteries, is a disease that is difficult to diagnose and treat. It includes a variety of rare diseases and is called “cancer of the heart and lung vascular system.” Without treatment, the average life span of patients is only 2.8 years. Pulmonary hypertension is a “carcinoma in cardiovascular disease” with a very high incidence and fatality rate. The number of patients worldwide is close to 100 million, but until now, pulmonary hypertension is still one of the lesser-known malignant diseases. Previously, the existing treatments for patients with pulmonary hypertension mainly relied on targeted drugs and lung transplantation. According to statistics from the US-Canada team in the article Pulmonary hypertension: the unaddressed global health burden published in Lancet Respiratory Medicine in 2018, the cost of drug treatment for patients with pulmonary hypertension is approximately US$80,000 per year. For most patients, this is an impossible expense to bear. As for lung transplantation, due to the limited source of organs and the common complications of infection and rejection in postoperative patients, lung transplantation is extremely difficult, and it is necessary to take anti-rejection drugs for a long time after surgery. In addition, the high cost of surgery also discourages patients.

Add a description here.

Subscribe

Sign up to our newsletter and stay up to date

Subscribed!

Thank you for subscribing to our newsletter.